TORONTO, Feb. 10, 2012 /CNW/ - Amorfix Life Sciences, a product
development company focused on diagnostics and therapeutics for
misfolded protein diseases, today announced its operational and
financial results for the third quarter ended December 31, 2011.
"This quarter was filled with outstanding scientific advances and steady
progress forward for all of our research programs" said Dr. Robert
Gundel, Amorfix President and Chief Executive Officer. "Our
collaboration with Helix BioPharma is on track to provide proof of
concept data for our cancer therapeutic antibody program and the FAS
receptor program continues to look very encouraging as we are now
preparing to test for binding and biological effects in a variety of
cellular assay systems. We entered into an LOI to license our AD
preclinical assay to JSW, a well recognized CRO, which will allow us to
focus more time on our research programs. We have initiated a new
program to develop a diagnostic blood test for ALS. At the present
time, clinicians must rely on a combination of clinical findings and
imaging technology to confirm the diagnosis, as there is no diagnostic
test or biomarker at their disposal. The availability of a simple blood
test has the potential to dramatically improve the ability of
clinicians to diagnose ALS at its beginning stages and offer
therapeutic intervention at a time when it could be most
beneficial. Finally, in January 2012, we closed the first tranche of a
private placement and raised gross proceeds of $677,820. We are
continuing our fundraising efforts to bring our programs to revenue
Recent Corporate Highlights
On November 17, 2011, the Company announced that it is developing a
blood test to be used as a diagnostic tool for amyotrophic lateral
sclerosis (ALS). Initial ground breaking scientific study results from
Amorfix Chief Scientific Officer Dr. Neil Cashman and colleagues at UBC
demonstrate that misfolded SOD1 is present in the blood of ALS
patients. The Company plans to capitalize on this discovery and
existing scientific expertise to develop a simple blood test that
measures misfolded SOD1 in blood. The Company has established key
intellectual property around misfolded SOD1 and its potential role in
neurodegenerative disease which covers the generation and use of any
diagnostic, therapeutic or vaccine involving misfolded SOD1.
On January 9, 2012 the Company announced that it has signed a letter of
intent with JSW-Lifesciences GmbH, a contract research organization
specializing in Alzheimer's and other CNS diseases, to license its
pre-clinical Alzheimer's disease diagnostic test, the Amorfix
Aggregated Abeta Assay (the A4). JSW plans to add the A4 to its suite of preclinical research services provided to
pharmaceutical companies and academic research institutions involved in
Alzheimer's disease research and development.
On January 18, 2012 the Company announced that it has closed the first
tranche of a non-brokered private placement (the Offering) pursuant to
which a total of 3,012,532 units (Units) were issued at a price of
$0.225 per unit for gross proceeds of $677,820. Each Unit consists of
one common share of Amorfix (a Share) and one common share purchase
warrant of Amorfix (a Warrant). Each Warrant entitles the holder to
purchase one Share at a price of $0.50 for a period of 36 months
following the closing date of the Offering, and is subject to earlier
expiry under certain conditions.
The net loss for the three months ended December 31, 2011 was $731,287
compared to a net loss of $810,029 for the three months ended December
31, 2010. The net loss for the nine months ended December 31, 2011 was
$1,841,496 compared to a net loss of $2,400,509 for the nine months
ended December 31, 2010.
For the three and nine months ended December 31, 2011 revenue from
services and sales was $18,554 and $90,882, respectively as compared to
$10,048 and $94,947 in the comparative periods. Substantially all of
this revenue was from the Company's A4 test. Revenue from license fees was $nil for the nine months ended
December 31, 2011 compared to $1,030,600 for the comparative period.
The Company entered into a license agreement with Biogen Idec in July
2010 and received a US$1,000,000 non-refundable fee.
Research and development expenditures for the three months ended
December 31, 2011 were $580,221 which is comparable to expenditures of
$609,185 in the comparable period. Research and development
expenditures for the nine months ended December 31, 2011 were
$1,511,375 compared to $2,703,453 in the comparable period. Research
and development expenditures decreased in the nine months ended
December 31, 2011 mainly from the Company having fewer employees than
in the comparable period, to the severance costs incurred in June 2010
associated with the decision to suspend commercialization of the
Company's vCJD program, and lower expenditures related to the ProMIS
and ALS therapeutic programs, offset by higher expenses on the AD
General and administrative costs for the three months ended December 31,
2011 were $171,961 compared to $219,670 in the comparable period and
for the nine months ended December 31, 2011 were $432,979 compared to
$864,407 in the comparable period. The decrease for the three and nine
months ended December 31, 2011 resulted mainly from the severance costs
incurred in the comparable periods and higher share based payment
expense recorded in the comparable periods.
At December 31, 2011, the Company had working capital of $619,211 and
50,609,959 common shares outstanding. Management projects that its
current working capital together with the net proceeds of the financing
completed in January 2012 will fund the Company's operations into the
first quarter of fiscal 2013. The Company is actively pursuing
financing alternatives, but there is no assurance that these
initiatives will be successful, timely or sufficient.
The Company's Fiscal 2012 and 2013 research priorities, subject to the
Company raising additional funds, are to:
Advance our ProMISTM antibody program targeting disease specific epitopes for both
therapeutics and companion diagnostics for cancer and other misfolded
protein diseases to a lead compound for late-stage preclinical
Complete the licensing of the company's A4 preclinical test.
Complete development of a human Alzheimer's test adapting the A4 test protocol to detect aggregated Abeta, the hallmark of the disease,
in human plasma and cerebro-spinal fluid;
Complete development of an ALS diagnostic test.
Additional information about the Company, including the MD&A and
financial results may be found on SEDAR at www.sedar.com.
Amorfix Life Sciences Ltd. (TSX: AMF) is a product development company
developing therapeutic products and diagnostic devices targeting
misfolded protein diseases including Alzheimer's Disease (AD), cancers,
and ALS. Amorfix utilizes its computational discovery platform,
ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the
molecular surface of misfolded proteins. Cancer immunotherapies have in
the past been directed against targets which are also present on normal
cells, whereas Amorfix's innovative ProMIS platform identifies targets
present only on cancer cells, retaining efficacy with improved safety.
Amorfix's lead programs include therapeutics and companion diagnostics
for cancers, antibodies and vaccines to DSEs in ALS, as well as AD and
ALS diagnostic tests. Amorfix's proprietary Epitope Protection™
technology enables it to specifically identify very low levels of
misfolded proteins in a biological sample. The Company's diagnostic
programs include an ultrasensitive method for the detection of
aggregated beta-Amyloid in brain tissue, CSF and blood from animal
models of AD, months prior to observable amyloid formation and the
development of a human screening test for AD and a blood test to
diagnose ALS. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release. This information release may
contain certain forward-looking information. Such information involves
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements
should not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs
as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations.
The Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Amorfix Life Sciences Ltd.
For further information:
Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899